Collaboration - April 20, 2016
Nuevolution expands collaboration
Nuevolution has announced that Janssen Biotech, one of the Pharmaceutical Companies of Johnson & Johnson, has used its option to expand the collaboration with Nuevolution, thereby providing Nuevolution with a further payment of 600,000 USD. Nuevolution A/S and Janssen Biotech entered into collaboration on 19 October, 2015 for application of Nuevolution’s proprietary Chemetics drug discovery platform […]
Intellectual Property - March 4, 2016
EPO has issued 4 new patents to Nuevolution
Swedish Nuevolution announces that the European Patent Office has issued four new patents to the company. In the Q2 2015/2016 report, Nuevolution announced that it was expecting three patents to be granted. Four patents (EP 1905829, EP 2305808, EP 2186897 and EP 1539980) from three different patent families have now issued in Europe. Nuevolution continues […]
Agreement - February 21, 2014
Nuevolution enters license agreement with Merck
Nuevolution A/S has announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc. The agreement involves small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development. Under terms of the agreement, Merck will gain exclusive rights for the further development and […]
Drug Development Pharma - January 22, 2014
Nuevolution enter drug discovery collaboration
The Institute of Cancer Research (ICR), London, Cancer Research Technology (CRT), London and Nuevolution, Copenhagen have entered into a drug discovery collaboration to identify novel lead candidates for cancer treatment. Researchers will use Nuevolution’s screening technology, Chemetics, to screen libraries each of millions of DNA-tagged compounds to identify those that act on a key protein in the stress […]
Agreement - January 10, 2014
Nuevolution Announces Technology Licensing Agreement
Nuevolution has announced that it has entered into a non-exclusive technology licensing agreement with Novartis for use of Nuevolution’s Chemetics technology. The Chemetics platform uses proprietary innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming drug-like small molecules for lead discovery. The technology allows efficient screening of billions of molecules against […]
Collaboration - November 8, 2013
Nuevolution in multi-target collaboration deal
The Denmark-based drug discovery company Nuevolution A/S has signed a collaboration deal with Cancer Research Technology to discover anti-cancer drug molecules. The collaboration aims to identify drug leads that block the activity of a number of cancer therapeutic targets. Through the partnership drug candidate molecules which home in on selected targets will be identified by […]
